Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

doi:10.1371/journal.pone.0067258

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

PloS one - 1 Jan 2013

Fang Douglas D, Zhang Cathy C, Gu Yin, Jani Jitesh P, Cao Joan, Tsaparikos Konstantinos, Yuan Jing, Thiel Melissa, Jackson-Fisher Amy, Zong Qing, Lappin Patrick B, Hayashi Tomoko, Schwab Richard B, Wong Anthony, John-Baptiste Annette, Bagrodia Shubha, Los Geritt, Bender Steve, Christensen James, Vanarsdale Todd

Abstract excerpt

PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors in both preclinical and clinical settings. In light of the recent discovery of tumor-initiating cancer stem cells (CSCs) in various tumor types, we developed an in vitro CSC model from xenograft tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Mice, SCID

Share to Neoplastic Stem Cells

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Pyridones

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 23826249
DOI: 10.1371/journal.pone.0067258
PMCID: PMC3695076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.PMID 23826249Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem CellsSemantic proximity Read ↗

Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.Semantic proximity Read ↗

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.Semantic proximity Read ↗

Therapeutic strategies against cancer stem cells in human colorectal cancer (Review)Semantic proximity Read ↗

Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosisSemantic proximity Read ↗

BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.Semantic proximity Read ↗

Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumabSemantic proximity Read ↗

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroidsSemantic proximity Read ↗

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical researchSemantic proximity Read ↗

Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.